Intervention not reported
Number of patients experiencing any adverse event · Patients with osteoarthritis of the knee or hip
The intervention showed no clear difference in number of patients experiencing any adverse event (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of patients who withdrew because of adverse events · Patients with osteoarthritis of the knee or hip
The intervention showed no clear difference in number of patients who withdrew because of adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of patients experiencing any serious adverse event Median · Patients with osteoarthritis of the knee or hip
1 finding from 1 review
Intervention not reported
Pain based on WOMAC pain scale Scale from: 0 (no pain) to 20 (worst pain). ( · patients with treating osteoarthritis
1 finding from 1 review
Intervention not reported
WOMAC Function Subscale Scale from: 0 to 68. ( · patients with treating osteoarthritis
1 finding from 1 review
Intervention not reported
Physician Global Assessment 100 mm visual analogue scale. Scale from: 0 to 100. ( · patients with treating osteoarthritis
1 finding from 1 review
Intervention not reported
Patient Global Assessment (patients rated whether they were better at the end of trial than at the start of the trial) ( · patients with treating osteoarthritis
The intervention showed no clear difference in patient Global Assessment (patients rated whether they were better… (moderate certainty).
1 finding from 1 review
Intervention not reported
Minimum Joint Space Width mm ( · patients with treating osteoarthritis
1 finding from 1 review
Intervention not reported
Toxicity (Number of Patients Reporting Adverse Events) · patients with treating osteoarthritis
The intervention showed no clear difference in toxicity (Number of Patients Reporting Adverse Events) (high certainty).
1 finding from 1 review
Intervention not reported
Toxicity (Number of Withdrawals due to Adverse Events) · patients with treating osteoarthritis
The intervention showed no clear difference in toxicity (Number of Withdrawals due to Adverse Events) (moderate certainty).
1 finding from 1 review
Intervention not reported
Pain based on WOMAC scale Scale from: 0 (no pain) to 20 (worst pain). ( · patients with treating osteoarthritis
1 finding from 1 review
Intervention not reported
WOMAC Function Subscale Scale from: 0 to 68. ( · patients with treating osteoarthritis
1 finding from 1 review
For outcome · patients with rheumatoid arthritis in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in pain (0‐100 mm VAS) · patients with rheumatoid arthritis in adults
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis in adults
1 finding from 1 review
ACR 50 response at 6 months · patients with rheumatoid arthritis in adults
Summary of findings: leflunomide leads to higher ACR 50 response at 6 months compared with placebo, 6 months (high certainty).
1 finding from 1 review
HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults
1 finding from 1 review
Pain change (0‐100 mm VAS) · patients with rheumatoid arthritis in adults
1 finding from 1 review
Radiographic joint changes · patients with rheumatoid arthritis in adults
Summary of findings: leflunomide showed no clear difference in radiographic change (Change in Sharp score) compared with placebo, 6 months (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis in adults
1 finding from 1 review